EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL

被引：0

作者：

Stephen, Boorjian A.

Vikram, Narayan M.

Viraj, Master A.

Badrinath, Konety R.

Neal, Shore D.

Ashish, Kamat M.

Colin, Dinney P. N.

Trinity, Bivalacqua J.

Max, Kates R.

Jeffrey, Montgomery S.

Seth, Lerner P.

Paul, Crispen L.

Gary, Steinberg D.

Piyush, Agarwal K.

Anne, Schuckman K.

Robert, Svatek S.

Brian, Lane R.

Lawrence, Karsh, I

Marc, Bjurlin A.

Gordon, Brown A.

Yair, Lotan

Brant, Inman A.

Michael, Williams B.

Michael, Cookson S.

Sam, Chang S.

Eric, Kim H.

Alexander, Sankin, I

Michael, O'Donnell A.

Jorn, Jakobsen S.

Kristian, Juul

机构：

[1] Mayo Clin, Dept Urol, Rochester, MN USA

[2] Emory Univ, Dept Urol, Sch Med, Atlanta, GA USA

[3] Univ Minnesota, Dept Urol, Minneapolis, MN USA

[4] Allina Hlth Canc Inst, Minneapolis, MN USA

[5] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA

[7] James Buchanan Brady Urol Inst, Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA

[8] Univ Michigan, Dept Urol, Ann Arbor, MI USA

[9] Baylor Coll Med, Scott Dept Urol, Houston, TX USA

[10] Univ Florida, Dept Urol, Gainesville, FL USA

[11] Rush Univ, Dept Urol, Chicago, IL USA

[12] Univ Chicago, Sect Urol, Dept Surg, Chicago, IL USA

[13] Univ Southern Calif, Inst Urol, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[14] Univ Texas Hlth San Antonio, Dept Urol, San Antonio, TX USA

[15] Michigan State Univ, Div Urol, Spectrum Hlth, Coll Human Med, Grand Rapids, MI USA

[16] Urol Ctr Colorado, Denver, CO USA

[17] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[18] Univ N Carolina, Dept Urol, Chapel Hill, NC USA

[19] New Jersey Urol, Bloomfield, NJ USA

[20] Univ Texas Southwestern Med Ctr, Dept Urol, Dallas, TX USA

[21] Duke Univ, Div Urol, Dept Surg, Sch Med, Durham, NC USA

[22] Urol Virginia, Virginia Beach, VA USA

[23] Univ Oklahoma, Dept Urol, Hlth Sci Ctr, Oklahoma City, OK USA

[24] Vanderbilt Univ, Div Urol Oncol, Nashville, TN USA

[25] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[26] Montefiore Med Ctr, Dept Urol, Bronx, NY USA

[27] Univ Iowa, Dept Urol, Iowa City, IA USA

[28] Ferring Pharmaceut A S, Copenhagen, Denmark

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2024年 / 42卷

关键词：

D O I：

10.1016/j.urolonc.2024.01.201

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

164

引用

页码：S70 / S70

页数：1

共 50 条

[1] EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH CARCINOMA IN SITU (CIS), BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC): LONGER-TERM FOLLOW-UP FROM THE PHASE III TRIAL
Schuckman, Anne K.
Lotan, Yair
Boorjian, Stephen A.
Cilwa, Katherine E.
Dinney, Colin P. N.
JOURNAL OF UROLOGY, 2021, 206 : E296 - E296
[2] Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial
Boorjian, S. A.
Narayan, V. M.
Konety, B. R.
Master, V. A.
Shore, N. D.
Kamat, A. M.
Bivalacqua, T. J.
Kates, M. R.
Montgomery, J. S.
Crispen, P. L.
Steinberg, G. D.
Agarwal, P. K.
Schuckman, A. K.
Karsh, L. I.
Bjurlin, M. A.
Brown, G. A.
Lotan, Y.
Inman, B. A.
Williams, M. B.
Cookson, M. S.
Chang, S. S.
Kim, E. H.
Sankin, A. I.
Dinney, C.
EUROPEAN UROLOGY, 2024, 85 : S1492 - S1493
[3] PHASE III TRIAL OF INTRAVESICAL NADOFARAGENE FIRADENOVEC IN PATIENTS WITH HIGH-GRADE, BCG-UNRESPONSIVE, NON-MUSCLE INVASIVE BLADDER CANCER: TWO YEAR FOLLOW-UP IN THE TA/T1 COHORT
Lotan, Yair
Schuckman, Anne K.
Boorjian, Stephen A.
Cilwa, Katherine E.
Dinney, Colin P. N.
JOURNAL OF UROLOGY, 2021, 206 : E296 - E296
[4] EVALUATING INTRAVESICAL NADOFARAGENE FIRADENOVEC AND IMMUNE CHECKPOINT BLOCKADE COMBINATION THERAPY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM A PHASE 3 TRIAL
Mitra, Anirban P.
Mokkapati, Sharada
Miest, Tanner S.
Narayan, Vikram M.
Philipson, Richard
Yla-Herttuala, Seppo
Sawutz, David
Parker, Nigel R.
McConkey, David J.
Dinney, Colin P. N.
JOURNAL OF UROLOGY, 2022, 207 (05): : E927 - E928
[5] Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Dinney, Colin P. N.
Narayan, Vikram M.
JOURNAL OF UROLOGY, 2024, 212 (04):
[6] Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Linscott, Joshua
Li, Roger
JOURNAL OF UROLOGY, 2024, 212 (04): : 624 - 625
[7] Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial
Boorjian, Stephen A.
Dinney, Colin P. N.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[8] Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Narayan, V.
Boorjian, S.
Alemozaffer, M.
Konety, B. R.
Gomella, L.
Kamat, A. M.
Lerner, S. P.
Svatek, R. S.
Karsh, L.
Canter, D.
Lotan, Y.
Inman, B. A.
Yang, M.
Garcia-Horton, V.
Sawutz, D.
Parker, N.
Dinney, C. P. N.
EUROPEAN UROLOGY, 2021, 79 : S1026 - S1027
[9] Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Narayan, Vikram M.
Boorjian, Stephen A.
Alemozaffar, Mehrdad
Konety, Badrinath R.
Shore, Neal D.
Gomella, Leonard G.
Kamat, Ashish M.
Bivalacqua, Trinity J.
Montgomery, Jeffrey S.
Lerner, Seth P.
Busby, Joseph E.
Poch, Michael
Crispen, Paul L.
Steinberg, Gary D.
Schuckman, Anne K.
Downs, Tracy M.
Mashni, Joseph
Lane, Brian R.
Guzzo, Thomas J.
Bratslavsky, Gennady
Karsh, Lawrence I.
Woods, Michael E.
Brown, Gordon
Canter, Daniel
Luchey, Adam
Lotan, Yair
Inman, Brant A.
Williams, Michael B.
Cookson, Michael S.
Chang, Sam S.
Sankin, Alexander I.
O'Donnell, Michael A.
Sawutz, David
Philipson, Richard
Parker, Nigel R.
Yla-Herttuala, Seppo
Rehm, Dorte
Jakobsen, Jorn S.
Juul, Kristian
Dinney, Colin P. N.
JOURNAL OF UROLOGY, 2024, 212 (01): : 74 - 86
[10] ANTI-ADENOVIRAL ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE IN BCG-UNRESPONSIVE NMIBC: RESULTS FROM A PHASE 3 TRIAL
Mitra, Anirban P.
Narayan, Vikram M.
Boorjian, Stephen A.
Alemozaffar, Mehrdad
Konety, Badrinath R.
Shore, Neal D.
Gomella, Leonard G.
Kamat, Ashish M.
Bivalacqua, Trinity J.
Montgomery, Jeffrey S.
Lerner, Seth P.
Busby, Joseph E.
Poch, Michael
Crispen, Paul L.
Steinberg, Gary D.
Schuckman, Anne K.
Downs, Tracy M.
Svatek, Robert S.
Mashni, Joseph, Jr.
Lane, Brian R.
Guzzo, Thomas J.
Bratslavsky, Gennady
Karsh, Lawrence I.
Woods, Michael E.
Brown, Gordon
Canter, Daniel
Luchey, Adam
Lotan, Yair
Krupski, Tracey
Inman, Brant A.
Williams, Michael B.
Cookson, Michael S.
Keegan, Kirk A.
Andriole, Gerald L., Jr.
Sankin, Alexander I.
Boyd, Alan
O'Donnell, Michael A.
Yang, Mindy
Sawutz, David
Philipson, Richard
Yla-Herttuala, Seppo
Parker, Nigel R.
Dinney, Colin P. N.
JOURNAL OF UROLOGY, 2021, 206 : E119 - E120

← 1 2 3 4 5 →